• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
TLX 2.97% $15.24

TELIX PHARMACEUTICALS LIMITED - Charts / Financials

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on... Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. The Company is developing a portfolio of clinical-stage products that focuses to address the unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). The Company’s lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases. The Company also owns SENSEI radio-guided surgery business.More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 03/05/2024 (20 minute delay) ?
Day
Open $14.71   Day High $15.24   Day Low $14.61
Daily Volume 1179463
Bids   Sellers
Number Price Volume   Number Price Volume
1 $15.15 2333   2 $15.25 10000

Directors & Senior Management

Dr. Christian P. Behrenbruch Group Chief Executive Officer, Managing Director, Executive Director
Mr. Darren Smith Group Chief Financial Officer
Mr. Raphael Ortiz Chief Executive Officer - APAC and EMEA
Mr. Kevin Richardson Chief Executive Officer, Americas
Dr. Darren Patti Group Chief Operating Officer
Ms. Lena Moran - Adams Group General Counsel
Dr. David Cade Group Chief Medical Officer
Mr. James Stonecypher Group Chief Development Officer
Mr. Richard Valeix Group Chief Commercial Officer
Ms. Genevieve Ryan Company Secretary
Mr. H. Kevin Mccann Non-Executive Independent Chairman of the Board
Dr. Andreas Kluge Non-Executive Director
Dr. Mark Nelson Non-Executive Independent Director
Ms. Tiffany P. Olson Non-Executive Independent Director
Ms. Jann Skinner Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
$15.24
Change
0.440(2.97%)
Mkt cap ! $5.036B
Open High Low Value Volume
$14.71 $15.24 $14.61 $17.69M 1.179M

Buyers (Bids)

No. Vol. Price($)
1 2333 $15.15
 

Sellers (Offers)

Price($) Vol. No.
$15.25 10000 2
View Market Depth
Last trade - 16.10pm 03/05/2024 (20 minute delay) ?
Last
$15.21
  Change
0.440 ( 2.60 %)
Open High Low Volume
$14.73 $15.24 $14.62 327752
Last updated 15.59pm 03/05/2024 ?
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.